Skip to main content

Clinical and Experimental Nephrology

Ausgabe Sonderheft 1/2020

Dotinurad: Novel URAT1 inhibitor

Inhalt (13 Artikel)

Open Access Original article

Clinical pharmacological study of dotinurad administered to male and female elderly or young subjects

Hiroshi Nakatani, Masahiko Fushimi, Tomomitsu Sasaki, Daisuke Okui, Tetsuo Ohashi

Open Access Original article

Effects of mild and moderate renal dysfunction on pharmacokinetics, pharmacodynamics, and safety of dotinurad: a novel selective urate reabsorption inhibitor

Hiroyuki Fukase, Daisuke Okui, Tomomitsu Sasaki, Masahiko Fushimi, Tetsuo Ohashi, Tatsuo Hosoya

Open Access Original article

Dotinurad: a clinical pharmacokinetic study of a novel, selective urate reabsorption inhibitor in subjects with hepatic impairment

Yuji Kumagai, Masashi Sakaki, Kenichi Furihata, Takayoshi Ito, Kazuaki Inoue, Takafumi Yoshida, Shigeki Matsumoto, Kazuki Furuno, Atsushi Hagino

Open Access Original article

Dotinurad versus benzbromarone in Japanese hyperuricemic patient with or without gout: a randomized, double-blind, parallel-group, phase 3 study

Tatsuo Hosoya, Takafumi Sano, Tomomitsu Sasaki, Masahiko Fushimi, Tetsuo Ohashi

Open Access Original article

Open-label study of long-term administration of dotinurad in Japanese hyperuricemic patients with or without gout

Tatsuo Hosoya, Masahiko Fushimi, Daisuke Okui, Tomomitsu Sasaki, Tetsuo Ohashi

Open Access Original article

A clinical pharmacology study of the novel, selective urate reabsorption inhibitor dotinurad in outpatients

Tatsuo Hosoya, Kazuki Furuno, Shingo Kanda

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.